Context Therapeutics (CNTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CNTX Context Therapeutics

Watchlist

1.1500
+0.1700+17.35%

Close Dec 24 13:00 ET

86.25MMarket Cap-1.31P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Context Therapeutics (CNTX) and Xenetic Biosciences (XBIO)
TipRanksDec 5 13:20 ET · Ratings
Context Therapeutics Secures Funding for Cancer Therapy Pipeline
TipRanksDec 2 16:51 ET
Express News | Context Therapeutics Enters $75M At-The-Market Offering Agreement, Allocating Proceeds To R&D, Working Capital, And Potential Asset Acquisitions
BenzingaDec 2 16:29 ET
Express News | Context Therapeutics Inc - Under Sales Agreement, May Offer & Sell up to $75 Million in Common Stock
ReutersDec 2 16:24 ET
Express News | Context Therapeutics Inc - Enters Sales Agreement With Leerink Partners
ReutersDec 2 16:24 ET
D. Boral Capital Initiates Coverage On Context Therapeutics With Buy Rating, Announces Price Target of $9
BenzingaNov 25 07:53 ET · Ratings

Comments

Trytosaveabit

Dec 23 15:02

8K filed today!

$Context Therapeutics (CNTX.US)$ On December 23, 2024, Context Therapeutics Inc. (the “Company”) sold 14,705,882 shares of its common stock, for aggregate gross proceeds of approximately $15 million. The shares were sold pursuant to a sales agreement with Leerink Partners LLC (the “Agent”) dated December 2, 2024. The Agent has informed the Company that the shares were purchased by MPM BioImpact LLC.